In 2009,Bethel, Paul A.; Gerhardt, Stefan; Jones, Emma V.; Kenny, Peter W.; Karoutchi, Galith I.; Morley, Andrew D.; Oldham, Keith; Rankine, Neil; Augustin, Martin; Krapp, Stephan; Simader, Hannes; Steinbacher, Stefan published 《Design of selective Cathepsin inhibitors》.Bioorganic & Medicinal Chemistry Letters published the findings.Recommanded Product: 847818-74-0 The information in the text is summarized as follows:
A number of chiral N-[1-(cyanomethylaminocarbonyl)-2-arylethyl]arylamides were synthesized. The mol. recognition features of the products have been exploited in structure-based design of selective Cathepsin inhibitors. The experimental process involved the reaction of 1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 847818-74-0Recommanded Product: 847818-74-0)
1-Methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrazole(cas: 847818-74-0) belongs to pyrazoles. Pyrazoles are commonly used scaffold molecules in drug discovery projects. The use of pyrazole derivatives is based on their analgesic, antipyretic, neuroleptic, anticonvulsant, antiarrhythmic, sedative, muscle relaxant, monoamine oxidase inhibitory, anti-inflammatory, antidiabetic and antibacterial activities. Recommanded Product: 847818-74-0
Referemce:
Pyrazole – Wikipedia,
Pyrazoles – an overview | ScienceDirect Topics